Start Dup15q and CAMK2 expertise centers
Recently, two new expertise have been launched under ENCORE! We can now welcome patients with CAMK2 Syndrome and Dup15q Syndrome at our ENCORE expertise center.
Continue ReadingNEPTUNE study for Angelman Syndrome completed
ENCORE participated in the international NEPTUNE study of the pharmaceutical company OVID. Four Dutch children participated in the study. The desired number of participants has now been reached, so no more children are enrolled. We expect the first results in early 2021.
Continue Reading